New findings on the diseases that crushed Napoleon’s army

As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever during the retreat from Russia.

Canada approves leqembi as global alzheimer’s drug race heats up

Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 15 major markets — one more than its closest rival, Eli Lilly’s Kisunla.

Swedish life science is growing – but capital is not keeping up

The number of employees and companies in Swedish life science is increasing and the sector is more equal than many other sectors. But investments in unlisted companies are weak.

A cluster contribution to European life science innovation and competitiveness?

Svensk life science växer – men kapitalet hänger inte med

Antalet anställda och antalet företag inom svensk life science ökar och sektorn är mer jämställd än många andra sektorer. Men investeringarna i onoterade bolag är svag.

Ny rapport: Små bolag lyfter svensk läkemedelsutveckling

Sveriges läkemedelsforskning fortsätter att gå starkt framåt, enligt en ny rapport från Sweden Bio. Landets projekt blir både fler och vassare – med småbolagen i spetsen.

How the Nobel discovery is used in drug development

Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how this finding is being applied in today’s drug development, and what challenges remain.

Flemingsberg – en växande nod för Life Science

Flemingsberg i södra Stockholm har länge varit hem för ett livskraftigt life science-kluster. Nu sker en tydlig acceleration då fler företag etablerar sig, samarbeten fördjupas och innovationskraften växer.

Sarah Lidé: ”Artificial intelligence must not replace authentic interactions”

Artificial intelligence must never become a replacement for authentic, even if messy, interactions with our fellow humankind, Sarah Lifé, Deputy CEO at Medicon Village Innovation, writes in a column.

Vd-byte i Frost Pharma

Frost Pharma har utsett Magnus Nylén till ny vd.

Första svenska patienten behandlad med Carvykti – ”Gått som planerat”

För första gången har en svensk patient behandlats med Carvykti, en CAR-T-cellterapi mot blodcancerformen multipelt myelom. Bakom behandlingen ligger flera års planeringsarbete och samverkan inom det nationella CAR-T-nätverket.

Heart Monitoring in Breast Cancer – Essential or Excessive?

Trastuzumab and related drugs have transformed breast cancer treatment and dramatically improved survival rates. But the close cardiac monitoring required during treatment can be a heavy burden for both patients and healthcare systems. Dr. Andri Papakonstantinou is working to refine how doctors identify which patients truly need intensive follow-up.

Astra Zeneca pauses multi-million investment in the UK

Astra Zeneca has paused a planned investment worth $270 million. It is the latest pharmaceutical company to pull back on its commitments in the UK.

Novo Nordisk tells staff to return to office

At the turn of the year, Novo Nordisk employees will no longer be able to work remotely. According to the company’s new CEO, the move is intended to accelerate decision-making and improve commercial execution as competition in the obesity drug market intensifies.

Flemingsberg – en växande nod för Life Science

Flemingsberg i södra Stockholm har länge varit hem för ett livskraftigt life science-kluster. Nu sker en tydlig acceleration då fler företag etablerar sig, samarbeten fördjupas och innovationskraften växer.

Tre nya ansikten på KI Innovations

Företagsinkubatorn KI Innovations har anställt tre nya medarbetare med bred erfarenhet från life science-sektorn.

Roche joins Medicon Village

Roche and Medicon Village Innovation have signed an agreement for deeper collaboration. “The fact that Roche is now becoming part of this environment further strengthens our concept,” says Medicon Village Innovation CEO Petter Hartman.

New ATMP center inaugurated: “In the future, we will see cell and gene therapies in all clinics”

Karolinska Institutet and Karolinska University Hospital’s new ATMP center was inaugurated in Flemingsberg, south of Stockholm. “The ATMP Center is not just a physical place, it is a promise,” said KI’s Vice-Chancellor Annika Östman Wernerson.

The top five most expensive drugs in 2025

New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in the US reveals a common denominator: all are gene therapies administered as one-time treatments.

BMS and venture capital giant form new company

The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company will develop treatments for autoimmune diseases where there is currently a lack of effective therapies.

Novo Nordisk appoints Mike Doustdar as new CEO

The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts – which caused the stock to drop sharply on Wednesday.

BMS och riskkapitaljätte bildar bolag för läkemedel mot autoimmuna sjukdomar

Det amerikanska läkemedelsbolaget Bristol Myers Squibb bildar tillsammans med riskkapitalbolaget Bain Capital ett nytt biotechbolag. Företaget ska utveckla behandlingar mot autoimmuna sjukdomar där det idag saknas välfungerande terapier.

FDA approves Gilead’s HIV injection: “Historic day”

Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally breaking the transmission chain of a virus that affects 1.3 million people annually.

Mercks RSV-läkemedel får tummen upp i USA – tar upp kampen med Beyfortus

Amerikanska FDA godkänner Mercks nya läkemedel mot infektioner orsakade av RS-virus. Därmed får Sanofis och Astra Zenecas storsäljare Beyfortus ny konkurrens.